Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTH NASDAQ:HEPA NASDAQ:LIPO NASDAQ:VRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.03-4.0%$0.06$0.01▼$0.23$282K-0.2920,947 shs56,455 shsHEPAHepion Pharmaceuticals$0.10+5.7%$0.05$0.03▼$0.11$491K1.5219,503 shs97,921 shsLIPOLipella Pharmaceuticals$0.04-0.5%$0.08$0.02▼$3.17$185K0.8317,614 shs1,127 shsVRAXVirax Biolabs Group$0.14+0.3%$0.16$0.10▼$1.19$610K1.064.61 million shs1.19 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path-4.00%-48.11%-53.85%-50.34%-83.99%HEPAHepion Pharmaceuticals+15.15%+58.33%+97.92%+58.33%-21.81%LIPOLipella Pharmaceuticals-0.50%+52.09%+81.82%-79.17%-98.33%VRAXVirax Biolabs Group+0.29%+3.70%-5.41%-32.24%-87.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.03-4.0%$0.06$0.01▼$0.23$282K-0.2920,947 shs56,455 shsHEPAHepion Pharmaceuticals$0.10+5.7%$0.05$0.03▼$0.11$491K1.5219,503 shs97,921 shsLIPOLipella Pharmaceuticals$0.04-0.5%$0.08$0.02▼$3.17$185K0.8317,614 shs1,127 shsVRAXVirax Biolabs Group$0.14+0.3%$0.16$0.10▼$1.19$610K1.064.61 million shs1.19 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path-4.00%-48.11%-53.85%-50.34%-83.99%HEPAHepion Pharmaceuticals+15.15%+58.33%+97.92%+58.33%-21.81%LIPOLipella Pharmaceuticals-0.50%+52.09%+81.82%-79.17%-98.33%VRAXVirax Biolabs Group+0.29%+3.70%-5.41%-32.24%-87.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path 0.00N/AN/AN/AHEPAHepion Pharmaceuticals 0.00N/AN/AN/ALIPOLipella Pharmaceuticals 0.00N/AN/AN/AVRAXVirax Biolabs Group 2.00Hold$1.00614.29% UpsideCurrent Analyst Ratings BreakdownLatest LIPO, VRAX, BPTH, and HEPA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2026VRAXVirax Biolabs Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/ALIPOLipella Pharmaceuticals$536.36K0.34N/AN/A$1.59 per share0.03VRAXVirax Biolabs Group$10K60.76N/AN/A$1.26 per share0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08M-$1.06N/AN/AN/AN/A-2,842.40%-337.48%N/AHEPAHepion Pharmaceuticals-$48.93M-$72.15N/AN/AN/AN/A-812.56%-207.31%N/ALIPOLipella Pharmaceuticals-$5.02M-$2.42N/AN/AN/A-988.83%-224.08%-172.88%6/3/2026 (Estimated)VRAXVirax Biolabs Group-$6.06MN/AN/AN/AN/AN/AN/AN/A6/3/2026 (Estimated)Latest LIPO, VRAX, BPTH, and HEPA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/AVRAXVirax Biolabs Group-$0.07N/AN/AN/A$0.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/AVRAXVirax Biolabs GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A0.860.86HEPAHepion PharmaceuticalsN/A1.301.30LIPOLipella PharmaceuticalsN/A6.216.21VRAXVirax Biolabs GroupN/A11.3711.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%HEPAHepion Pharmaceuticals17.24%LIPOLipella Pharmaceuticals74.31%VRAXVirax Biolabs Group8.61%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path0.72%HEPAHepion Pharmaceuticals0.06%LIPOLipella Pharmaceuticals32.11%VRAXVirax Biolabs Group45.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path109.81 million5.73 millionNo DataHEPAHepion Pharmaceuticals2011.44 million6.63 millionNo DataLIPOLipella Pharmaceuticals44.62 million3.03 millionNot OptionableVRAXVirax Biolabs Group54.34 million2.38 millionNot OptionableLIPO, VRAX, BPTH, and HEPA HeadlinesRecent News About These CompaniesVirax Biolabs Group Ltd - Ordinary Shares - Class AMay 13 at 9:25 AM | money.usnews.comVirax Biolabs Group Limited Or Stock Short Interest Rises to 71.68%April 25, 2026 | quiverquant.comQVirax Biolabs Group Ltd. Class AApril 24, 2026 | edition.cnn.comVirax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to ShareholdersApril 14, 2026 | prnewswire.comVirax Biolabs Announces Full Exercise of Pre-Funded Warrants From $5 Million Private PlacementApril 10, 2026 | tipranks.comWhat's Behind The Jump In Virax Biolabs Stock?March 31, 2026 | benzinga.comVirax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical ValidationMarch 31, 2026 | prnewswire.comVirax Biolabs Group (VRAX) price target decreased by 95.00% to 1.02February 5, 2026 | msn.comVirax Biolabs Sets March 11, 2026 AGM to Vote on Reverse Share Split and New Equity PlanJanuary 30, 2026 | tipranks.comVirax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's WhyJanuary 15, 2026 | zacks.comVirax Biolabs secures $5 million in private placement to advance immunology researchDecember 4, 2025 | msn.comVirax Biolabs Group Limited Announces Closing of $5 Million Private PlacementDecember 4, 2025 | prnewswire.comVirax Biolabs Group Limited Announces $5 Million Private PlacementDecember 3, 2025 | prnewswire.comVirax Biolabs stock rockets after clinical progress in post-infection diagnosticsDecember 3, 2025 | investing.comVirax Biolabs soars as company advances diagnostics for post-infection syndromesDecember 3, 2025 | msn.comVirax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to ShareholdersDecember 3, 2025 | prnewswire.comVirax BioLabs Group Limited: Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune Study Evaluating T Cell Dysfunction in Post ...November 3, 2025 | finanznachrichten.deVirax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection SyndromesNovember 3, 2025 | prnewswire.comVirax Biolabs (VRAX) Falls 18% on Lack of LeadsAugust 27, 2025 | insidermonkey.comVirax BioLabs Group Limited: Virax Biolabs Partners with Emory University on ViraxImmune Clinical Studies; Readies for FDA Pre-Submission Meeting in Early SeptemberAugust 27, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLIPO, VRAX, BPTH, and HEPA Company DescriptionsBio-Path NASDAQ:BPTH$0.03 0.00 (-4.00%) As of 05/14/2026 03:48 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Hepion Pharmaceuticals NASDAQ:HEPA$0.10 +0.01 (+5.67%) As of 05/14/2026 03:16 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Lipella Pharmaceuticals NASDAQ:LIPO$0.04 0.00 (-0.50%) As of 05/14/2026 03:44 PM EasternLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.Virax Biolabs Group NASDAQ:VRAX$0.14 +0.00 (+0.29%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$0.14 -0.01 (-3.57%) As of 04:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
